Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 28, 2020 - Issue 8
Submit an article Journal homepage
279
Views
7
CrossRef citations to date
0
Altmetric
Original Article

The Relationship between Fluorescein Angiography Leakage after Infliximab Therapy and Relapse of Ocular Inflammatory Attacks in Ocular Behçet’s Disease Patients

Shintaro Shirahama1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
, MD,
Toshikatsu Kaburaki1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence[email protected]
View further author information
, MD, PhD,
Junko Matsuda2 Department of Ophthalmology, Nerima Hikarigaoka Hospital, Tokyo, JapanView further author information
, MD,
Rie Tanaka1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
, MD,
Hisae Nakahara1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
, MD,
Keiko Komae1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
, MD,
Hidetoshi Kawashima3 Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, JapanView further author information
, MD, PhD &
Makoto Aihara1 Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
, MD, PhD show all
Pages 1166-1170 | Received 26 Mar 2019, Accepted 05 Jul 2019, Published online: 14 Aug 2019

REFERENCES

  • Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9:241–245. PMID: 19879978. doi:10.1016/j.autrev.2009.10.005.
  • Nussenblatt RB. Uveitis in Behçet’s disease. Int Rev Immunol. 1997;14:67–79. PMID: 9203027. doi:10.3109/08830189709116845.
  • Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014;5:112–134. doi:10.1177/2040622314523062.
  • Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology. 2007;46:1161–1164. PMID: 17478466. doi:10.1093/rheumatology/kem101.
  • Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368. PMID: 15229958.
  • Tugal-Tutkun I, Herbort CP, Khairallah M. Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–552. doi:10.1007/s10792-008-9263-x.
  • Kaburaki T, Namba K, Sonoda KH, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–130. PMID: 24482146. doi:10.1007/s10384-013-0294-0.
  • Adl MA, LeHoang P, Bodaghi B. Use of fluorescein angiography in the diagnosis and management of uveitis. Int Ophthalmol Clin. 2012;52:1–12. PMID: 22954925. doi:10.1097/IIO.0b013e3182662e49.
  • Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. British J Ophthalmol. 2011;95:1245–1250. PMID: 21183514. doi:10.1136/bjo.2010.194464.
  • Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536–543. PMID: 23053631. doi:10.1007/s10384-012-0182-z.
  • Suzuki Kurokawa M, Suzuki N. Behcet’s disease. Clin Exp Med. 2004;4:10–20. PMID: 15598081. doi:10.1007/s10238-004-0033-4.
  • Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458. PMID: 23208313. doi:10.1038/bmt.2012.244.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.